Publications by authors named "Hans Loibner"

Claim this Profile
F
Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial.
Holger N Lode, Nikolai Siebert, Dominique Valteau-Couanet, Alberto Garaventa, Adela Canete, Hans Loibner

Clin Cancer Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study.
Holger N Lode, Karoline Ehlert, Stephanie Huber, Sascha Troschke-Meurer, Nikolai Siebert, Hans Loibner

Br J Cancer· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Response and Outcome of High-Risk Neuroblastoma Patients Immunized with Anti-Idiotypic Antibody Ganglidiomab: Results from Compassionate-Use Treatments.
Leah Klingel, Nikolai Siebert, Sascha Troschke-Meurer, Maxi Zumpe, Karoline Ehlert, Hans Loibner

Cancers (Basel)· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1).
Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel, Hans Loibner

Cancers (Basel)· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2.
Sascha Troschke-Meurer, Nikolai Siebert, Madlen Marx, Maxi Zumpe, Karoline Ehlert, Hans Loibner

Oncoimmunology· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel, Hans Loibner

Lancet Oncol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma.
Mark R Albertini, Richard K Yang, Erik A Ranheim, Jacquelyn A Hank, Cindy L Zuleger, Hans Loibner

Cancer Immunol Immunother· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial.
Nikolai Siebert, Sascha Troschke-Meurer, Madlen Marx, Maxi Zumpe, Karoline Ehlert, Hans Loibner

Cancers (Basel)· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-Specific Inhibition of Vaccination by Distant Untreated Tumor Sites.
Zachary S Morris, Emily I Guy, Lauryn R Werner, Peter M Carlson, Clinton M Heinze, Hans Loibner

Cancer Immunol Res· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD antibody ch14.18/CHO.
Ina Mueller, Karoline Ehlert, Stefanie Endres, Lena Pill, Nikolai Siebert, Hans Loibner

MAbs· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Charge heterogeneity: Basic antibody charge variants with increased binding to Fc receptors.
Beate Hintersteiner, Nico Lingg, Peiqing Zhang, Susanto Woen, Kong Meng Hoi, Hans Loibner

MAbs· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.
Alexander L Rakhmilevich, Mildred Felder, Lauren Lever, Jacob Slowinski, Kayla Rasmussen, Hans Loibner

J Immunol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2.
Nikolai Siebert, Christin Eger, Diana Seidel, Madlen Jüttner, Maxi Zumpe, Hans Loibner

MAbs· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microheterogeneity of therapeutic monoclonal antibodies is governed by changes in the surface charge of the protein.
Beate Hintersteiner, Nico Lingg, Evelyne Janzek, Oliver Mutschlechner, Hans Loibner

Biotechnol J· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutrophil/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy.
Christoph Suppan, Vesna Bjelic-Radisic, Marlen La Garde, Andrea Groselj-Strele, Katharina Eberhard, Hans Loibner

BMC Cancer· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preoperative neutrophil-to-lymphocyte ratio predicts clinical outcome in patients with stage II and III colon cancer.
Gudrun Absenger, Joanna Szkandera, Michael Stotz, Ulrich Postlmayr, Martin Pichler, Hans Loibner

Anticancer Res· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects.
Manuel Haschke, Manfred Schuster, Marko Poglitsch, Hans Loibner, Marc Salzberg

Clin Pharmacokinet· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adoptive transfer of siRNA Cblb-silenced CD8+ T lymphocytes augments tumor vaccine efficacy in a B16 melanoma model.
Reinhard Hinterleitner, Thomas Gruber, Christa Pfeifhofer-Obermair, Christina Lutz-Nicoladoni, Alexander Tzankov, Hans Loibner

PLoS One· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recombinant Expression and Characterization of Human and Murine ACE2: Species-Specific Activation of the Alternative Renin-Angiotensin-System.
Marko Poglitsch, Oliver Domenig, Cornelia Schwager, Stefan Stranner, Bernhard Peball, Hans Loibner

Int J Hypertens· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytoskeletal defects in Bmpr2-associated pulmonary arterial hypertension.
Jennifer A Johnson, Anna R Hemnes, Daniel S Perrien, Manfred Schuster, Linda J Robinson, Hans Loibner

Am J Physiol Lung Cell Mol Physiol· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recombinant angiotensin-converting enzyme 2 suppresses pulmonary vasoconstriction in acute hypoxia.
Axel Kleinsasser, Iris Pircher, Benedict Treml, Martin Schwienbacher, Manfred Schuster, Hans Loibner

Wilderness Environ Med· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2.
JiuChang Zhong, Danny Guo, Christopher B Chen, Wang Wang, Manfred Schuster, Hans Loibner

Hypertension· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression.
Jiu-Chang Zhong, Jia-Ying Ye, Hai-Yan Jin, Xi Yu, Hui-Min Yu, Hans Loibner

Regul Pept· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction.
JiuChang Zhong, Ratnadeep Basu, Danny Guo, Fung L Chow, Simon Byrns, Hans Loibner

Circulation· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension.
Jan Wysocki, Minghao Ye, Eva Rodriguez, Francisco R González-Pacheco, Clara Barrios, Hans Loibner

Hypertension· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis